|
Complications, No./total No. (%)
|
|
Shock
|
16/116 (13.8)
|
0/61 (0.0)
|
16/55 (29.1)
|
< 0.0001
|
|
Acute cardiac injury
|
23/116 (19.8)
|
4/61 (6.6)
|
19/55 (34.5)
|
0.001
|
|
Acute respiratory distress syndrome
|
20/116 (17.2)
|
0/61 (0.0)
|
20/55 (36.4)
|
< 0.0001
|
|
Liver dysfunction
|
15/116 (12.9)
|
2/61 (3.3)
|
13/55 (23.6)
|
0.0011
|
|
Acute kidney injury
|
3/116 (2.6)
|
0/61 (0.0)
|
3/55 (5.5)
|
0.0565
|
|
Acute heart failure
|
21/116 (18.1)
|
3/61 (4.9)
|
18/55 (32.7)
|
0.0002
|
|
Treatment, No./total No. (%)
|
|
Administration of oseltamivir
|
91/116 (78.4)
|
46/61 (75.4)
|
45/55 (81.8)
|
0.4019
|
|
Administration of lopinave/litonawe (LPV/r)
|
74/116 (63.8)
|
42/61 (68.9)
|
32/55 (58.2)
|
0.2325
|
|
Administration of arbidolhydrochloride
|
27/116 (23.3)
|
15/61 (24.6)
|
12/55 (21.8)
|
0.7243
|
|
Administration of ribavirin injection
|
71/116 (61.2)
|
37/61 (60.7)
|
34/55 (61.8)
|
0.8979
|
|
Administration of antibiotics
|
113/116 (97.4)
|
58/61 (95.1)
|
55/55 (100.0)
|
0.0956
|
|
Use of antifungal medications
|
12/116 (10.3)
|
0/61 (0.0)
|
12/55 (21.8)
|
0.0001
|
|
Administration of systemic corticosteroids
|
55/116 (47.4)
|
14/61 (23.0)
|
41/55 (74.5)
|
< 0.0001
|
|
Oxygen inhalation
|
103/116 (88.8)
|
50/61 (82.0)
|
53/55 (96.4)
|
0.0141
|
|
Noninvasive ventilation
|
18/116 (15.5)
|
0/61 (0.0)
|
18/55 (32.7)
|
< 0.0001
|
|
Invasive mechanical ventilation
|
10/116 (8.6)
|
0/61 (0.0)
|
10/55 (18.2)
|
0.0005
|
|
Extracorporeal membrane oxygenation
|
3/116 (2.6)
|
0/61 (0.0)
|
3/55 (5.5)
|
0.0646
|
|
Use of intravenous immunoglobin
|
74/116 (63.8)
|
25/61 (41.0)
|
49/55 (89.1)
|
< 0.0001
|
|
Use of thymopeptidesinjection
|
92/116 (79.3)
|
45/61 (73.8)
|
47/55 (85.5)
|
0.1209
|
|
Traditional Chinese medical herbal treatment
|
103/116 (88.8)
|
55/61 (90.2)
|
48/55 (87.3)
|
0.2955
|
|
Clinical outcomes, No./total No. (%)
|
|
Discharge from hospital
|
109/116 (94.0)
|
61/61 (100.0)
|
48/55 (87.3)
|
0.0040
|
|
Death
|
7/116 (6.0)
|
0/61 (0.0)
|
7/55 (12.7)
|
0.0040
|
